FIELD: chemistry.
SUBSTANCE: invention relates to a compound of general formula (I), its stereoisomer or its pharmaceutically acceptable salt. In formula (I): ring A is selected from phenyl and 
; ring B is selected from
Ra and Rb are independently selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl and C1-C6 alkyl substituted with substitutes independently selected from halogen, C3-C6 cycloalkyl, C1-C6 alkoxy C1-C6 alkyl and 5- or 6-membered heterocyclyl containing 1–3 heteroatoms selected from O, N or S; Rc and Rd are independently selected from hydrogen, halogen, -OH, -OC1-C6 alkyl, C1-C6 alkyl, halogen C1-C6 alkyl, perhalogen C1-C6 alkyl, C1-C6 alkoxy C1-C6 alkyl, -C(=O)5- or 6-member heterocyclyl containing 1–3 heteroatoms, selected from O, N or S, and 5- or 6-member heterocyclyl containing 1–3 heteroatoms selected from O, N or S; optionally groups Rc and Rd together with the carbon atom to which they are attached form C3-C6 cycloalkyl, 5- or 6-membered heterocycle containing 1–3 heteroatoms selected from O, N or S, and 5- or 6-membered heterocyclyl containing 1–3 heteroatoms selected from O, N or S, substituted with 1–2 substitutes selected from oxo and C1-C6 alkyl; R1 is selected from C1-C6 alkyl and C3-C6 cycloalkyl; R2 and R3 are independently selected from hydrogen, halogen and C1-C6 alkyl; R4 is selected from halogen, -NH2, C1-C6 alkyl, perhalogen C1-C6 alkyl, C3-C6 cycloalkyl substituted with hydroxy C1-C6 alkyl, 5- or 6-membered heterocyclyl containing 1–3 heteroatoms selected from O, N or S, and C1-C6 alkyl substituted with substitutes independently selected from halogen, -OH, perhalogen C1-C6 alkyl, -OC1-C6 alkyl, -NHC1-C6 alkyl, -N(C1-C6 alkyl)2 and 5- or 6-membered heterocyclyl containing 1–3 heteroatoms selected from O, N or S; and n represents an integer selected from 0, 1, 2 and 3. Also disclosed is a pharmaceutical composition and use of the compound of formula (I).
EFFECT: disclosed compound is an inhibitor of SOS1 and can be used to treat diseases or disorders mediated by SOS1.
17 cl, 9 tbl, 160 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS OF 1-CYANO-PYRROLIDINES AS USP30 INHIBITORS | 2016 |
|
RU2717238C2 |
| PYRIDAZINE DERIVATIVES AS RORc MODULATORS | 2017 |
|
RU2757571C2 |
| JAK KINASE-MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF APPLYING THEREOF | 2010 |
|
RU2529019C2 |
| TREATMENT METHOD | 2012 |
|
RU2621148C2 |
| AZETIDINE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVING ANTIMICROBIAL ACTIVITY | 1991 |
|
RU2044735C1 |
| SPIRO CONDENSED PYRROLIDINE DERIVATIVES AS INHIBITORS OF DEUBIQUITINATING ENZYMES (DUB) | 2017 |
|
RU2730552C2 |
| PROTEIN KINASE INHIBITORS FOR ENHANCING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | 2019 |
|
RU2822216C2 |
| TRICYCLIC PYRROLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND USE THEREOF AS KINASE INHIBITORS | 2012 |
|
RU2591191C2 |
| NOVEL LIGANDS OF ESTROGEN RECEPTORS | 2009 |
|
RU2492164C2 |
| (AZA)INDOLE-, BENZOTHIOPHENE- AND BENZOFURAN-3-SULPHONAMIDES | 2017 |
|
RU2767904C2 |
